Trials / Active Not Recruiting
Active Not RecruitingNCT03822897
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.
Detailed description
The standard or usual treatment for this disease includes radiotherapy or radiotherapy combined with chemotherapy or antibody therapy. These treatments are highly effective at curing most patients with HPV-related cancer of the oropharynx, but short and long-term side effects from treatment can be significant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiation | 35 fractions, 5/wk, 7 wks 70Gy/56Gy, or 35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or 35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy |
| DRUG | Cisplatin | 100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks |
Timeline
- Start date
- 2019-06-28
- Primary completion
- 2024-06-25
- Completion
- 2026-12-31
- First posted
- 2019-01-30
- Last updated
- 2026-02-17
- Results posted
- 2025-09-30
Locations
14 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03822897. Inclusion in this directory is not an endorsement.